棘白菌素类抗真菌药物预防侵袭性念珠菌血症有效性与安全性的Meta分析
2020-07-09李莎戴立波姚海涛孔旭东
李莎 戴立波 姚海涛 孔旭东



摘 要目的:系統评价棘白菌素类抗真菌药物预防侵袭性念珠菌血症的有效性及安全性,为临床治疗提供循证参考。方法:计算机检索PubMed、Embase、Medline、Cochrane图书馆、中国期刊全文数据库、中文科技期刊数据库、万方数据,检索时限为建库起至2019年7月,收集棘白菌素类药物(试验组)对比常规抗真菌药物(两性霉素B及三唑类抗真菌药,对照组)预防侵袭性念珠菌血症有效性和安全性的随机对照试验(RCT),对符合纳入标准的临床研究进行资料提取并采用Cochrane系统评价员手册5.0.2进行质量评价后,采用Rev Man 5.2 统计软件对突破性侵袭性真菌感染率、真菌感染死亡率、全因死亡率及因不良反应停药的发生率进行Meta 分析。结果:共纳入7项RCT,合计3 219例患者。Meta 分析结果显示,试验组患者突破性侵袭性真菌感染发生率[OR=0.58,95%CI(0.40,0.85),P=0.004]、真菌感染死亡率[OR=0.68,95%CI(0.51,0.92),P=0.01]和因不良反应停药的发生率[OR=0.52,95%CI(0.40,0.67),P<0.001]均显著低于对照组,差异均有统计学意义;两组患者全因死亡率比较,差异无统计学意义[OR=0.84,95%CI(0.67,1.05),P=0.13]。结论:与两性霉素B及三唑类抗真菌药比较,棘白菌素类药物用于预防侵袭性念珠菌血症可降低突破性侵袭性真菌感染发生率、真菌感染死亡率和因不良反应停药的发生率。
关键词 棘白菌素;预防;侵袭性念珠菌血症;随机对照试验;有效性;安全性;Meta分析
中图分类号 R978.5 文献标志码 A 文章编号 1001-0408(2020)01-0104-06
DOI 10.6039/j.issn.1001-0408.2020.01.18
ABSTRACT OBJECTIVE: To systematically evaluate the efficacy and safety of echinococcins in the prevention of invasive candidiasis, and to provide evidence-based reference for clinical treatment. METHODS: Retrieved from PubMed, Embase, Medline, Cochrane library, CJFD, VIP and Wanfang database, randomized controlled trials (RCTs) about the effectiveness and safety of echinococcins (trial group) versus conventional fungal drugs (amphotericin B and triazole antifungal agents, control group) in the prevention of invasive candidiasis were collected during database establishment to Jul. 2019. After data extraction of clinical studies met inclusion criteria and quality evaluation with Cochrane system evaluator manual 5.0.2, Meta-analysis was performed for breakthrough invasive fungal infection rate, fungal infection mortality rate, all-cause mortality rate and the incidence of drug withdrawal due to adverse reactions by using Rev Man 5.2 statistical software. RESULTS: Totally 7 RCTs were included, involving 3 219 patients. Results of Meta-analyses indicated that the incidence of breakthrough invasive fungal infection [OR=0.58,95%CI (0.40,0.85),P=0.004], fungal infection mortality rate[OR=0.68,95%CI (0.51,0.92),P=0.01] and the incidence of drug withdrawal due to adverse reactions [OR=0.52,95%CI (0.40,0.67),P<0.001] in trial groups were significantly lower than control group, with statistical significance. There was no statistical significance in the all-cause mortality rate [OR=0.84,95%CI (0.67,1.05),P=0.13]. CONCLUSIONS: Compared with amphotericin B and triazole antifungal agents, echinococcins used for the prevention of invasive candidiasis can reduce the incidence of breakthrough invasive fungal infection, fungal infection mortality rate and the incidence of drug withdrawal due to adverse reactions.
KEYWORDS Echinococcins; Prevention; Invasive candi- diasis; Randomized controlled trials; Efficacy; Safety; Meta- analysis
免疫功能受損患者发生侵袭性念珠菌菌血症的风险极高,高危人群包括血液系统恶性肿瘤患者、实体器官移植或造血干细胞移植(Hematopoietic stem cell transplantation,HSCT)受者及使用过化疗药物的患者,尤其是使用过广泛损害胃肠道黏膜药物的患者,感染早期诊断存在困难,延迟启动治疗会造成不良结局,因此,需早期预防真菌感染[1-2]。Cornely OA等[3]调查了13个欧洲癌症中心267例侵袭性念珠菌菌血症患者,结果显示白色念珠菌和非白色念珠……
